Brenden O’Hara, RPh, BCACP, from Blue Cross Blue Shield of North Carolina, talked about the pharmacist’s role in improving outcomes in value-based contracts and why collaboration is needed.
Brenden O’Hara, RPh, BCACP, is a clinical pharmacist in Provider Engagement Initiatives at Blue Cross Blue Shield of North Carolina.
Transcript:
How can pharmacists improve outcomes in value-based contracts, particularly in the use of specialty therapies?
O’Hara: Lots of different ways. So, what we do in working with our pharmacists is understanding what their day entails and what their work is already doing, and then help support them with data and information and additional views of some of the members that would have that direct desired outcome—direct potential cost of care and different quality improvement outcomes. We share that information with our partners.
Specialty is definitely a big focus. We're not having many of our chronic disease state medications coming out. It's all going to be these specialty medications at high costs. We must pay attention to these high cost drivers and look for alternatives. Sometimes there's just not alternatives and it's just accepting that this is going to be a high-cost patient, high-cost therapy, but looking for other areas for opportunities to help control costs for those members.
Ideally, across the board, you're trying to control them, but sometimes you can't. If it's a cancer patient or a patient with cystic fibrosis, with some very unique disease states, if you meet all the criteria, there's not much to do. The medications are fantastic, and they do a great job at helping manage the disease state. So, you might look at other areas that you actually have the potential for impact.
Why is it important for collaboration to happen between health plans and pharmacists for value-based contracts?
O’Hara: A lot of the work is already happening in each individual area. So, there's a lot that health plans are doing to help manage cost of care and identify opportunities for savings. Health systems are doing it as well, whether that be for making sure that patients are on the right medications and adherent to it and improving outcomes and decreasing disease state burdens or [emergency department] visits.
But since we're doing it separately and now we have an opportunity with value-based contracts, together we win. So, if I can collaborate with health systems or different practitioners in different areas and help them save money, the health plan saves money and, together, we share those savings. That's the whole purpose of these value-based contracts.
So, the collaboration is a lot about the relationship building, but it's [also about] understanding that we're already doing this work individually and how do we do it together. How do we understand what each individual is doing and do the work together to have synergistic effects and higher-level effects by working together?
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More